Madrigal Believes It Holds The Key To NASH: Clearing The Fat
Executive Summary
Emerging Company Profile: With its first-in-class selective THR beta agonist, Madrigal thinks it may have a candidate, now in Phase II, that will offer reversal of liver damage in NASH patients with an excellent safety profile. It hopes to begin Phase III studies with MGL-3196 before the end of 2018.
You may also be interested in...
Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction
Analysts and investors also voice excitement about the THR-beta agonist's lipid-lowering effects to date. For Madrigal, the key will be replicating its 12-week data at 36 weeks, when the trial ends.
Intercept’s NASH Phase III Enrolling Slowly; Gilead Could Gain Ground
As Gilead’s ASK1 inhibitor nears Phase III, Intercept may be plagued by slower-than-expected enrollment of its Phase III trial for Ocaliva. A recent Biomedtracker survey finds liver docs may be more positively inclined toward the Gilead candidate.
In Novartis, Conatus Lands Experienced, Deep-Pocketed NASH Partner
Biotech gets $50m up front, up to $650m in milestones, significant royalties and the option to co-promote emricasan in NASH in the US. Novartis also may combine the caspase inhibitor with its Phase II FXR agonist.